Sansure Biotech released an announcement of performance increase on January 18, and it is expected that the net profit attributable to the owners of the parent company will be realized from 2.556 billion yuan to 2.8626 billion yuan in 2020. It will increase by 251,678 compared with the same period of the previous year (statutory disclosure data) from 10,000 yuan to 2,766.78 billion yuan. 

Sansure Biotech stated in the announcement that the main reason for the changes in the performance of the current period was that during the reporting period, the company actively responded to the needs of the global fight against the COIVD-19, developed corresponding epidemic prevention and control products in a relatively short period of time, and simultaneously equipped with professional after-sales and The technical support team provided customers with a full range of services in a timely and effective manner, which better met the needs of the global market. As a result, the sales of COVID-19 nucleic acid detection reagents, nucleic acid detection instruments, and related consumables increased substantially. 

At the same time, the company's instrument sales and installed capacity growth further drove the company's incremental sales of all reagents. In 2020, a total of 6,122 instruments were shipped. Therefore, the aforementioned situation has had a positive impact on the 2020 annual performance.